Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phase II study shows Arcalyst reduces gout flares by 81%

Sep. 4, 2008

Agile achieves phase II study endpoints with low-dose contraceptive patch

Sep. 4, 2008

FDA approves Sandoz's Omnitrope Pen 10 with liquid cartridge for growth hormone deficiency

Sep. 4, 2008

Neurocrine presents elagolix PETAL study results in endometriosis

Sep. 4, 2008

New agents for treating obesity and nutritional disorders presented in recent patents

Sep. 3, 2008

7TM commences phase I/IIa TM-30339 for the treatment of obesity

Sep. 2, 2008

New treatment options for diabetes disclosed in recent patent literature

Sep. 2, 2008

Opioid receptor antagonist GSK-982 reduces food intake in obese and lean rats

Sep. 2, 2008

Growth hormone secretagogue BMS-606056 displays promising preclinical characteristics

Sep. 1, 2008

Takeda and Affymax focus Hematide development on kidney-related anemia

Aug. 29, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...